BroPair Spiromax

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

salmeterol xinafoate, fluticasone propionat

Available from:

Teva B.V.

ATC code:

R03AK06

INN (International Name):

salmeterol, fluticasone propionate

Therapeutic group:

Zdravila za obstruktivne pljučne bolezni,

Therapeutic area:

Astma

Therapeutic indications:

BroPair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Product summary:

Revision: 1

Authorization status:

Pooblaščeni

Authorization date:

2021-03-26

Patient Information leaflet

                                25
Uporabite v 2 mesecih od odstranitve zdravila iz folije.
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 25 °C. Pokrovček ustnika naj bo po
odstranitvi zdravila iz folije zaprt.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH ZDRAVIL
ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Teva B.V., Swensweg 5, 2031GA Haarlem, Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/21/1534/001
13.
ŠTEVILKA SERIJE
_ _
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
_ _
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
BroPair Spiromax 12,75 mikrograma/100 mikrogramov prašek za
inhaliranje
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
26
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA ZA SKUPNO PAKIRANJE (S PODATKI ZA T.I. MODRO OKENCE)
1.
IME ZDRAVILA
BroPair Spiromax 12,75 mikrograma/100 mikrogramov prašek za
inhaliranje
salmeterol/flutikazonijev proprionat
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
En dostavljeni odmerek (odmerek iz ustnika) vsebuje 12,75 mikrograma
salmeterola (v obliki
salmeterolijevega ksinafoata) in 100 mikrogramov flutikazonijevega
propionata.
En odmerjeni odmerek vsebuje 14 mikrogramov salmeterola (v obliki
salmeterolijevega ksinafoata) in
113 mikrogramov flutikazonijevega propionata.
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje laktozo. Glejte navodilo za uporabo za več informacij.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
prašek za inhaliranje
Skupno pakiranje: 3 inhalatorji (3 pakiranja z 1 inhalatorjem).
En inhalator vsebuje 60 odmerkov.
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Za inhaliranje.
Pred uporabo preberite navodilo za uporabo.
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN POGLEDA
OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
Uporabite po navodilih zdravnika.
SPREDNJI DEL: NE UPORABLJAJTE PRI OTROCIH, MLAJŠIH OD 12 LET.
Ne zaužijte suši
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
BroPair Spiromax 12,75 mikrograma/100 mikrogramov prašek za
inhaliranje
BroPair Spiromax 12,75 mikrograma/202 mikrograma prašek za
inhaliranje
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
En dostavljeni odmerek (odmerek iz ustnika) vsebuje 12,75 mikrograma
salmeterola (v obliki
salmeterolijevega ksinafoata) in 100 mikrogramov ali 202 mikrograma
flutikazonijevega propionata.
En odmerjeni odmerek vsebuje 14 mikrogramov salmeterola (v obliki
salmeterolijevega ksinafoata) in
113 mikrogramov ali 232 mikrogramov flutikazonijevega propionata.
Pomožne snovi z znanim učinkom:
En dostavljeni odmerek vsebuje približno 5,4 miligrama laktoze (v
obliki monohidrata).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
prašek za inhaliranje
bel prašek
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo BroPair Spiromax je indicirano za redno zdravljenje astme pri
odraslih in mladostnikih, starih 12 let
in več, pri katerih bolezen ni ustrezno nadzorovana z inhalacijskimi
kortikosteroidi in kratkodelujočimi
inhalacijskimi agonisti adrenergičnih receptorjev β
2
, ki so predpisani za uporabo po potrebi.
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
Bolnikom je treba pojasniti, da morajo za najboljši učinek zdravilo
BroPair Spiromax uporabljati vsak dan,
tudi kadar nimajo simptomov.
Če se simptomi pojavijo v obdobjih med odmerki, je treba za
takojšnje olajšanje uporabiti inhalacijski
kratkodelujoči agonist adrenergičnih receptorjev beta
2
.
Pri izbiri jakosti začetnega odmerka zdravila BroPair Spiromax
(12,75/100 mikrogramov srednjega odmerka
inhalacijskega kortikosteroida [ICS -
_inhaled cortikosteroid_
] ali 12,75/202 mikrograma velikega odmerka
ICS) je treba upoštevati resnost bolnikove bolezni, predhodno
zdravljenja astme, vključno z odmerkom ICS,
in trenuten nadzor simptomov astme.
Bolnike mora zdravnik redno kontrolirati, da ostane uporabljana jakost
salmeterola/flutikazonijevega
proprionata optimalna in se spremeni le
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 27-08-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 27-08-2021
Public Assessment Report Public Assessment Report Bulgarian 14-04-2021
Patient Information leaflet Patient Information leaflet Spanish 27-08-2021
Public Assessment Report Public Assessment Report Spanish 14-04-2021
Patient Information leaflet Patient Information leaflet Czech 27-08-2021
Public Assessment Report Public Assessment Report Czech 14-04-2021
Patient Information leaflet Patient Information leaflet Danish 27-08-2021
Public Assessment Report Public Assessment Report Danish 14-04-2021
Patient Information leaflet Patient Information leaflet German 27-08-2021
Public Assessment Report Public Assessment Report German 14-04-2021
Patient Information leaflet Patient Information leaflet Estonian 27-08-2021
Public Assessment Report Public Assessment Report Estonian 14-04-2021
Patient Information leaflet Patient Information leaflet Greek 27-08-2021
Public Assessment Report Public Assessment Report Greek 14-04-2021
Patient Information leaflet Patient Information leaflet English 27-08-2021
Public Assessment Report Public Assessment Report English 14-04-2021
Patient Information leaflet Patient Information leaflet French 27-08-2021
Public Assessment Report Public Assessment Report French 14-04-2021
Patient Information leaflet Patient Information leaflet Italian 27-08-2021
Public Assessment Report Public Assessment Report Italian 14-04-2021
Patient Information leaflet Patient Information leaflet Latvian 27-08-2021
Public Assessment Report Public Assessment Report Latvian 14-04-2021
Patient Information leaflet Patient Information leaflet Lithuanian 27-08-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 27-08-2021
Public Assessment Report Public Assessment Report Lithuanian 14-04-2021
Patient Information leaflet Patient Information leaflet Hungarian 27-08-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 27-08-2021
Public Assessment Report Public Assessment Report Hungarian 14-04-2021
Patient Information leaflet Patient Information leaflet Maltese 27-08-2021
Public Assessment Report Public Assessment Report Maltese 14-04-2021
Patient Information leaflet Patient Information leaflet Dutch 27-08-2021
Public Assessment Report Public Assessment Report Dutch 14-04-2021
Patient Information leaflet Patient Information leaflet Polish 27-08-2021
Public Assessment Report Public Assessment Report Polish 14-04-2021
Patient Information leaflet Patient Information leaflet Portuguese 27-08-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 27-08-2021
Public Assessment Report Public Assessment Report Portuguese 14-04-2021
Patient Information leaflet Patient Information leaflet Romanian 27-08-2021
Public Assessment Report Public Assessment Report Romanian 14-04-2021
Patient Information leaflet Patient Information leaflet Slovak 27-08-2021
Public Assessment Report Public Assessment Report Slovak 14-04-2021
Patient Information leaflet Patient Information leaflet Finnish 27-08-2021
Public Assessment Report Public Assessment Report Finnish 14-04-2021
Patient Information leaflet Patient Information leaflet Swedish 27-08-2021
Public Assessment Report Public Assessment Report Swedish 14-04-2021
Patient Information leaflet Patient Information leaflet Norwegian 27-08-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 27-08-2021
Patient Information leaflet Patient Information leaflet Icelandic 27-08-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 27-08-2021
Patient Information leaflet Patient Information leaflet Croatian 27-08-2021
Public Assessment Report Public Assessment Report Croatian 14-04-2021